QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.058206v1 308/2/474    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fish, E. W. Articles by Miczek, K. A. Search for Related Content PubMed PubMed Citation Articles by Fish, E. W. Articles by Miczek, K. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CITALOPRAM HYDROBROMIDE PYRILAMINE

BEHAVIORAL PHARMACOLOGY

Anxiolytic-Like Effects of Escitalopram, Citalopram, and R-Citalopram in Maternally Separated Mouse Pups

Department of Psychology (E.W.F., S.F., K.A.M.) and Department of Psychiatry, Pharmacology, and Neuroscience (K.A.M.), Tufts University, Medford and Boston, Massachusetts; and Department of Pharmacology and Toxicology (S.G.), Forest Research Institute, Jersey City, New Jersey

The S-enantiomer of citalopram, escitalopram, is a selective serotonin reuptake inhibitor (SSRI) that appears to be responsible for citalopram's antidepressant and anxiolytic effects. Clinically, escitalopram is reported to have fewer adverse side effects than do other SSRIs. This study compared escitalopram to other antidepressants in a preclinical procedure predicting anxiolytic-like effects of drugs. Carworth Farms Webster (CFW) mouse pups (7 days old) were separated from the dam and maintained at a temperature of 34°C. Forty-five minutes after administering citalopram (0.56–10 mg/kg), escitalopram (0.0056–3 mg/kg), R-citalopram (1–10 mg/kg), paroxetine (0.3–3 mg/kg), fluoxetine (1–30 mg/kg), or venlafaxine (3–56 mg/kg) subcutaneously, the pups were placed individually on a 19.5°C surface for 4 min. Ultrasonic vocalizations (USVs) (30–80 kHz), grid crossing, rolling (i.e., the pup turned on one side or its back), and colonic temperature were recorded. All the drugs reduced USV emission; escitalopram was the most potent (ED₅₀ 0.05 mg/kg), followed by paroxetine (0.17 mg/kg), citalopram (1.2 mg/kg), fluoxetine (4.3 mg/kg), R-citalopram (6 mg/kg), and venlafaxine (7 mg/kg)_. The doses that decreased USVs differed from those that increased motor activity. Increased grid crossing occurred after low doses of paroxetine (0.03 or 0.1 mg/kg) and fluoxetine (1 mg/kg), but only after the highest doses of the citalopram enantiomers and venlafaxine (0.3, 10, and 56 mg/kg, respectively). Except for escitalopram and venlafaxine, high doses of the treatments increased rolling. R-Citalopram caused a 10-fold rightward shift in escitalopram's dose-effect curve, suggesting that R-citalopram inhibits escitalopram's anxiolytic-like effects. These data support clinical findings that escitalopram is a potent, well tolerated SSRI with anxiolytic-like effects.

Address correspondence to: Klaus A. Miczek, Tufts University, 530 Boston Ave. (Bacon Hall), Medford, MA 02155. E-mail klaus.miczek{at}tufts.edu

This article has been cited by other articles:

				S. Pinheiro, C. Del-Ben, H. Zangrossi Jr, and F. Graeff Anxiolytic and panicolytic effects of escitalopram in the elevated T-maze J Psychopharmacol, March 1, 2008; 22(2): 132 - 137. [Abstract] [PDF]

				S. A. Kromer, M. S. Kessler, D. Milfay, I. N. Birg, M. Bunck, L. Czibere, M. Panhuysen, B. Putz, J. M. Deussing, F. Holsboer, et al. Identification of Glyoxalase-I as a Protein Marker in a Mouse Model of Extremes in Trait Anxiety J. Neurosci., April 27, 2005; 25(17): 4375 - 4384. [Abstract] [Full Text] [PDF]